MAIA Biotechnology, Inc. (MAIA) |
|
1.61 0.15 (10.27%)
|
09-27 16:00 |
|
Open: |
1.5 |
Pre. Close: |
1.46 |
|
High:
|
1.64 |
Low:
|
1.5 |
|
Volume:
|
74,279 |
Market Cap:
|
22(M) |
|
|
|
Technical analysis |
as of: 2023-09-27 4:20:39 PM |
|
Short-term rate:
|
  |
| Stoxline posted a STRONG BUY today, upgraded from lower rating. Upward movement to be expected. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 2.18 One year: 2.51 |
| Support: |
Support1: 1.41 Support2: 1.18 |
| Resistance: |
Resistance1: 1.87 Resistance2: 2.15 |
| Pivot: |
1.62  |
| Moving Average: |
MA(5): 1.51 MA(20): 1.67
MA(100): 2.13 MA(250): 3.06 |
| MACD: |
MACD(12,26): -0.2 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 17.7 %D(3): 14.9 |
| RSI: |
RSI(14): 43.6 |
| 52-week: |
High: 5.21 Low: 1.41 |
| Average Vol(K): |
3-Month: 30 (K) 10-Days: 35 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ MAIA ] has closed above bottom band by 47.3%. Bollinger Bands are 17.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.64 - 1.65 |
1.65 - 1.66 |
|
Low:
|
1.48 - 1.49 |
1.49 - 1.5 |
|
Close:
|
1.6 - 1.61 |
1.61 - 1.62 |
|
Company Description |
|
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois. |
Headline News |
Tue, 08 Aug 2023
MAIA Biotechnology Reports Second Quarter 2023 Financial Results and Provides Updates for THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer - Yahoo Finance
Mon, 10 Jul 2023
MAIA Biotechnology Reports Updates on Preliminary Survival Data ... - Business Wire
Tue, 20 Jun 2023
MAIA Biotechnology Announces Updates in Enrollment in Phase II ... - Business Wire
Wed, 07 Jun 2023
MAIA Biotechnology Files Second Patent For New Telomere ... - Business Wire
Thu, 27 Apr 2023
MAIA Biotechnology, Inc. Announces Closing of Public Offering - Business Wire
Mon, 24 Apr 2023
MAIA Biotechnology, Inc. Announces Pricing of Public Offering - Business Wire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: AMEX |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
0 (M) |
|
% Held by Insiders
|
0 (%) |
|
% Held by Institutions
|
0 (%) |
|
Shares Short
|
0 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
0 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
0 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
0 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
